|Year : 2015 | Volume
| Issue : 3 | Page : 251-253
Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with lung adenocarcinoma
Arzu Cengiz1, Mine Sencan Eren1, Mehmet Polatli2, Yakup Yürekli1
1 Department of Nuclear Medicine, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey
2 Department of Pulmonology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey
|Date of Web Publication||11-Jun-2015|
Department of Nuclear Medicine, Faculty of Medicine, Adnan Menderes University, Aydin
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Hypertrophic pulmonary osteoarthropathy (HPOA) is not an uncommon paraneoplastic syndrome that is frequently associated with lung cancer. A 54-year-old male patient with lung adenocarcinoma underwent bone scintigraphy and fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for initial staging. Bone scintigraphy revealed increased periosteal activity in lower extremities. FDG PET/CT revealed hypermetabolic right lung mass, mediastinal lymph nodes, and mildly increased periosteal FDG uptake in both femurs and tibias. The findings in lower extremities on bone scan and FDG PET/CT were interpreted as HPOA.
Keywords: Adenocarcinoma of lung, hypertrophic osteoarthropathy, periostitis, positron emission tomography/computed tomography
|How to cite this article:|
Cengiz A, Eren MS, Polatli M, Yürekli Y. Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with lung adenocarcinoma. Indian J Nucl Med 2015;30:251-3
|How to cite this URL:|
Cengiz A, Eren MS, Polatli M, Yürekli Y. Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with lung adenocarcinoma. Indian J Nucl Med [serial online] 2015 [cited 2022 Jan 18];30:251-3. Available from: https://www.ijnm.in/text.asp?2015/30/3/251/158535
| Introduction|| |
Hypertrophic pulmonary osteoarthropathy (HPOA) is often associated with lung carcinoma, but other intrathoracic tumors or nonmalignant diseases including hepatopulmonary syndrome of advanced liver or cirrhosis, cyanotic heart diseases may also associated with this clinical condition. , It is distinguished by painful, swollen joints, digital clubbing, and periostitis. , Radiologically, periostitis presents as new bone formation and appearance of a smooth layer to the bones. Bone scintigraphy is a highly sensitive method for the diagnosis of HPOA and the typical scintigraphic presentation is a diffuse, symmetrically increased uptake in the diaphysis and metaphysis of tubular bones, with a distinctive double stripe or parallel track sign.  In addition, diffuse moderately increased fluorodeoxyglucose (FDG) uptake in the periostea of long bones had been reported. ,
Here, we present a lung cancer patient who demonstrated findings consistent with HPOA on bone scintigraphy and FDG positron emission tomography/computed tomography (PET/CT) imaging.
| Case report|| |
A 54-year-old male patient complaining of cough, generalized bone pain and weakness was referred to our hospital. He was smoking for 30 years/1 packet/day. On physical examination, he had Grade I clubbing of fingers and toes. Complete blood count and biochemistry tests were normal except mild anemia. CT of the thorax demonstrated 5 cm × 6 cm mass lesion with speculated margins in the upper lobe of the right lung. In addition, there was mediastinal lymphadenopathy. Bronchoscopy and biopsy were done, and histopathology revealed adenocarcinoma of the lung. The patient was referred nuclear medicine department for bone scintigraphy and 18F-FDG PET/CT. Bone scintigraphy was performed 3 h after intravenous injection of 20 mCi (740 MBq) methylene diphosphonate (MDP). It demonstrated no osseous metastases but revealed increased periosteal activity in the long bones of the legs corresponding to hypertrophic osteoarthropathy [Figure 1]. PET/CT images were acquired 60 min after intravenous injection of 7 mCi (259 MBq) FDG an integrated PET/CT camera. Maximum intensity projection and transaxial images showed increased FDG accumulation in the primary tumor (SUVmax: 17), mediastinal lymph nodes (SUVmax: 3.3) and mild, symmetrical periosteal FDG uptake along both femuri and tibias (SUVmax: 2.4-3.0) [Figure 2].
|Figure 1: Three-hour whole body Tc-99m methylene diphosphonate images shows intense periosteal uptake in the long bones of the legs|
Click here to view
|Figure 2: Maximal intensity projection (a) transaxial positron emission tomography (PET) (b) transaxial fusion of lower extremities (c) and transaxial fusion of thorax (d) PET/computed tomography imaging show increased fluorodeoxyglucose accumulation in the primary tumor and mediastinal lymph nodes as well as along periosteum of long bones of legs in a symmetrical fashion with an SUVmax 2.4-3.0|
Click here to view
| Discussion|| |
Hypertrophic pulmonary osteoarthropathy is a commonly seen paraneoplastic manifestation of lung cancer or some nonmalignant diseases.
Incidences of HPOA of 0.2-17% in lung cancer patients have been reported. ,,,,,, In a study, Ito et al. analyzed lung cancer patients with HPOA and were found to have more often HPOA in males, adenocarcinoma subtype, heavy smokers and Stage IIIb and V diseases.  Our patient's diagnosis was adenocarcinoma, and he was the current smoker. In published reports, adenocarcinoma accounted for 11-53% of lung cancer patients with HPOA. ,,,,
The pathogenesis of periostitis and HPOA is unclear. Involvement of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and platelets in the pathogenesis of HPOA has been indicated in some publications. ,, They found that plasma VEGF and PDGF levels were significantly higher in patients with HPOA compared with healthy controls.
Hypertrophic pulmonary osteoarthropathy is diagnosed based on clinical symptoms such as continuous pain and edema in the extremities and imaging findings. Periostitis is the hallmark of HPOA and bone radiography reveals periosteal membrane thickening and periosteal new bone formation.  Magnetic resonance imaging findings in patients with HPOA were described in a number of cases and observed soft-tissue changes and periostitis. The findings consisted of the muscular and septal edema associated with extensive soft-tissue swelling that surrounded the femur and the attached cortex. Periostitis appeared as a wavy, thin, hypointense line surrounding the cortex. ,
Bone scintigraphy is a highly sensitive method for the detection of HPOA. The typical scintigraphic presentation is a diffuse symmetrically increased uptake in the diaphysis and metaphysis of tubular bones with a distinctive double stripe or parallel track sign.  Makis et al. also showed mild hyperemia surrounding the long bones of the legs at blood pool images and intense Tc-99m MDP uptake in the periostea at delayed bone scan imaging.  Recently, increased FDG uptake along the periosteum of long bones at PET/CT imaging was shown in some reports. , In this case, increased FDG uptake was observed concordant with the inflammatory reaction in the periostea of the lower extremities.
| Conclusion|| |
Bone scintigraphy and FDG PET show increased metabolic activity in the long bones of patients with HPOA. Physicians interpreting PET/CT images should be aware of these findings especially in patients with lung cancer. Correct interpretation of bone scan as well as PET/CT findings is important to make proper treatment decisions. Hence, nuclear medicine physicians should be aware and familiar with these findings and avoid reporting them as bone metastases.
| References|| |
Stokkel MP, Valdés Olmos RA, Hoefnagel CA, Richel DJ. Tumor and therapy associated abnormal changes on bone scintigraphy. Old and new phenomena. Clin Nucl Med 1993;18:821-8.
Armstrong DJ, McCausland EM, Wright GD. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): Two cases presenting as acute in inflammatory arthritis. Description and review of the literature. Rheumatol Int 2007;27:399-402.
Yeung SC, Habra MA, Thosani SN. Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med 2011;17:260-8.
Myers KA, Farquhar DR. The rational clinical examination. Does this patient have clubbing? JAMA 2001;286:341-7.
Qian X, Qin J. Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett 2014;7:2079-082.
Makis W, Abikhzer G, Rush C. Hypertrophic pulmonary osteoarthropathy diagnosed by FDG PET-CT in a patient with lung adenocarcinoma. Clin Nucl Med 2009;34:625-7.
Strobel K, Schaefer NG, Husarik DB, Hany TF, Steinert H. Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT. Clin Nucl Med 2006;31:624-6.
Hirakata Y, Kitamura S. Pulmonary hypertrophic osteoarthropathy and clubbing of fingers in patients with lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:1080-5.
Honma H. Etiology of pulmonary hypertrophic osteoarthropathy. Nihon Rinsho 1975;33:392-7.
Segal AM, Mackenzie AH. Hypertrophic osteoarthropathy: A 10-year retrospective analysis. Semin Arthritis Rheum 1982;12:220-32.
Kroon HM, Pauwels EK. Bone scintigraphy for the detection and follow-up of hypertrophic osteoarthropathy. Diagn Imaging 1982;51:47-55.
Katsuyama N, Yamaguchi K, Takano H. A case of hypertrophic osteoarthropathy secondary to lung cancer. Rinsho Hoshasen 1988;33:1117-8.
Morgan B, Coakley F, Finlay DB, Belton I. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin Radiol 1996;51:694-7.
Ito T, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al.
Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010;5:976-80.
Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004;203:721-8.
Silveira LH, Martínez-Lavín M, Pineda C, Fonseca MC, Navarro C, Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000;18:57-62.
Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C. Hypertrophic osteoarthropathy: Endothelium and platelet function. Clin Rheumatol 1996;15:435-9.
Capelastegui A, Astigarraga E, García-Iturraspe C. MR findings in pulmonary hypertrophic osteoarthropathy. Clin Radiol 2000;55:72-5.
Sainani NI, Lawande MA, Parikh VP, Pungavkar SA, Patkar DP, Sase KS. MRI diagnosis of hypertrophic osteoarthropathy from a remote childhood malignancy. Skeletal Radiol 2007;36 Suppl 1:S63-6.
[Figure 1], [Figure 2]